Xian-Janssen has obtained approval from China's State FDA for Velcade (bortezomib) for treatment of mantle cell lymphoma, representing China's first drug for the disease. MCL, originating in the lymph nodes, is a lymphoma subtype with poor prognosis and short survival time. In China, its incidence rate ranks 9 and 10 respectively in all male and female malignant tumors. Bortezomib appeared as the world's first targeted protease inhibitor and received approval from U.S. FDA in 2008 for first- and second-line treatment for multiple myeloma and MCL, respectively. According to Phase II clinical trials jointly conducted by 35 clinical centers in the U.S., U.K. and Germany, bortezomib single-agent has shown effectiveness in the treatment of relapsed or refractory MCL. (Click here for more - Chinese language)
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.
Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.
As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?
